reports
Danske Bank AS: 1 director
A director at Danske Bank AS sold 80,305 shares at 195.460DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Danske Bank A/S, transactions by persons discharging managerial respon...
Danske Bank A/S, transactions by persons discharging managerial responsibilities 17 May 2024 Notification no. 52/2024 Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation. In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata. For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them...
Coloplast A/S - Invitation to Coloplast's Meet the Management event on...
Coloplast A/S - Invitation to Coloplast's Meet the Management event on 6 June 2024 (gentle reminder) The event will take place on Thursday, 6 June 2024 at Coloplast’s HeadquartersHoltedam 3, 3050 Humlebaek, Denmarkfrom 11.30 - 18.00 CEST (Central European Summer Time) Coloplast invites institutional investors, equity analysts and media to attend our 2024 Meet the Management event.The event will be held in person at our headquarters in Humlebaek, Denmark, with the option to join us virtually for the plenary session.The purpose of the event is to provide participants with the opportuni...
Danske Bank A/S, ledende medarbejderes transaktioner
Danske Bank A/S, ledende medarbejderes transaktioner 15. maj 2024 Indberetning nr. 51/2024 Ændring i aktiebesiddelser hos Danske Banks indberetningspligtige i henhold til EU-forordningen om markedsmisbrug I forbindelse med Danske Bank A/S’ aktietilbagekøbsprogram sælger APMH Invest A/S løbende aktier i Danske Bank A/S pro rata. For yderligere detaljer henvises til de vedhæftede skemaer, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til disse skal indberettes og offentliggøres. Kontakt: Stefan Singh Kailay, Head of Media...
Danske Bank A/S, transactions by persons discharging managerial respon...
Danske Bank A/S, transactions by persons discharging managerial responsibilities 15 May 2024 Notification no. 51/2024 Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation. In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata. For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. Contact: Stef...
Coloplast udvider Luja™-portefølje med nyt kateter til kvinder
Coloplast udvider Luja™-portefølje med nyt kateter til kvinder Engangskateteret gør det muligt for kvinder at tømme blæren i et frit flow1, hvilket nedsætter risikoen for urinvejsinfektioner2. Luja-platformen er med sin Micro-hole Zone Technology en ny generation af intermitterende engangskatetre til mennesker med behov for hjælp til at tømme deres blære. Efter en vellykket lancering af Luja til mandlige kateterbrugere lancerer Coloplast nu Luja til kvinder. ”Vi har modtaget rigtig god feedback for Luja til mænd i vores produktevalueringer. Næsten alle sundhedsprofessionelle anbefaler kat...
Coloplast expands its Luja™ portfolio with next generation catheter fo...
Coloplast expands its Luja™ portfolio with next generation catheter for women The female intermittent catheter enables complete bladder emptying in one free flow1, aiming to reduce the risk of urinary tract infections2. Following the successful launch of Luja with Micro-hole Zone Technology, a next generation intermittent catheter for men, Coloplast is now launching Luja for women. “So far, we have received great feedback on Luja for men in our product evaluations. Nearly all healthcare professionals would recommend the male catheter to their patients3, and sev...
Danske Bank A/S, ledende medarbejderes transaktioner
Danske Bank A/S, ledende medarbejderes transaktioner 14. maj 2024 Indberetning nr. 50/2024 Ændring i aktiebesiddelser hos Danske Banks indberetningspligtige i henhold til EU-forordningen om markedsmisbrug I forbindelse med Danske Bank A/S’ aktietilbagekøbsprogram sælger APMH Invest A/S løbende aktier i Danske Bank A/S pro rata. For yderligere detaljer henvises til de vedhæftede skemaer, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til disse skal indberettes og offentliggøres. Kontakt: Stefan Singh Kailay, Head of Media...
Danske Bank A/S, transactions by persons discharging managerial respon...
Danske Bank A/S, transactions by persons discharging managerial responsibilities 14 May 2024 Notification no. 50/2024 Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation. In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata. For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them...
- ABGSC Financials Research
- Patrik Brattelius
Danske Bank share buy-back programme: Transactions in week 19
Danske Bank share buy-back programme: Transactions in week 19 Company announcement no. 20 2024 Group CommunicationsBernstorffsgade 40DK-1577 København VTel. 13 May 2024 Danske Bank share buy-back programme: Transactions in week 19 On 2 February 2024, Danske Bank A/S announced a share buy-back programme for a total of DKK 5.5 billion, with a maximum of 70 million shares, in the period from 5 February 2024 to 31 January 2025, at the latest, as described in company announcement no. 2 2024. The programme is being carried out under Regulation (EU) No. 596/2014 of the European Parliament and o...
- ABGSC Healthcare Research
- Morten Larsen
- Rune Majlund Dahl
Coloplast (Buy, TP: DKK1050.00) - Next up: ‘Meet the Management’
Q2 organic growth of 7.5% YOY was in line with our forecast and consensus, but the EBIT margin (b.s.i.) of 27.2% missed. Coloplast revised its 2023/24 reported revenue growth guidance to 10–11% (previously c11%) on FX, but kept its c8% organic growth and 27–28% EBIT margin (b.s.i.) guidance. At the upcoming ‘Meet the Management’ event, we expect an update on its clinical performance programme and a deep-dive into Kerecis. We reiterate our BUY and DKK1,050 target price.
Danske Bank A/S, ledende medarbejderes transaktioner
Danske Bank A/S, ledende medarbejderes transaktioner 7. maj 2024 Indberetning nr. 49/2024 Ændring i aktiebesiddelser hos Danske Banks indberetningspligtige i henhold til EU-forordningen om markedsmisbrug I forbindelse med Danske Bank A/S’ aktietilbagekøbsprogram sælger APMH Invest A/S løbende aktier i Danske Bank A/S pro rata. For yderligere detaljer henvises til de vedhæftede skemaer, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til disse skal indberettes og offentliggøres. Kontakt: Stefan Singh Kailay, Head of Media ...
- Martin Marandon-Carlhian
- Stephane Houri
FME FRESENIUS MEDICAL CARE AG & CO. KGAA
RCO REMY COINTREAU SA
LONN LONZA GROUP AG
EN BOUYGUES SA
ADEN ADECCO GROUP AG
SCR SCOR SE
ZAL ZALANDO SE
GEBN GEBERIT AG
HEI HEIDELBERGCEMENT AG
SOLB SOLVAY SA
COLO B COLOPLAST A/S CLASS B
BP. BP P.L.C.
SHL SIEMENS HEALTHINEERS AG
UN0 UNIPER SE
- Martin Marandon-Carlhian
- Stephane Houri
INFINEON INFINEON TECHNOLOGIES AG
FME FRESENIUS MEDICAL CARE AG & CO. KGAA
RCO REMY COINTREAU SA
LONN LONZA GROUP AG
EN BOUYGUES SA
ADEN ADECCO GROUP AG
SCR SCOR SE
ZAL ZALANDO SE
GEBN GEBERIT AG
HEI HEIDELBERGCEMENT AG
SOLB SOLVAY SA
COLO B COLOPLAST A/S CLASS B
BP. BP P.L.C.
SHL SIEMENS HEALTHINEERS AG
UN0 UNIPER SE
- Oliver Metzger
Coloplast : Q2 review – Top and bottom line a slight miss, focus on LC...
>Q2 review – Miss on top and bottom line - Coloplast’s Q2 2024 revenues of DKK 6,586m (+8.7% y-o-y) were -1%/-2% vs ODDO BHF/consensus, driven by organic growth of 8% (7.3%/7.6% ODDO BHF/consensus). External growth contributed to the tune of 4% and forex created a headwind of 300bp. Coloplast achieved an EBIT of DKK 1,772m (+7.3% y-o-y, margin 26.9%), which was -3%/-4% vs expectations. Profitability was supported by operating leverage and efficiency savings but impact...
- ABGSC Healthcare Research
- Morten Larsen
Coloplast styrker stomiporteføljen med tre nye produktlanceringer
Coloplast styrker stomiporteføljen med tre nye produktlanceringer Selskabet har fået refusionsgodkendelse i Storbritannien for Heylo™, verdens første digitale notifikationssystem til at opdage lækage, og udvider samtidig sin SenSura® Mio-produktserie med to nye lanceringer. Da vi lancerede vores 2025-strategi, Strive25, satte vi et klart mål om at hæve behandlingsstandarden for vores brugere og bringe nye produkter hurtigere til markedet. Jeg glæder mig over at se, at vores innovationsteam bliver ved med at levere, senest med lanceringen af disse tre nye stomiprodukter, fortæller Colopl...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.